Astec LifeSciences Limited reported a significant decline in financial performance for Q2 FY25, with total income down 10.1% to Rs 100.5 crore compared to Q2 FY24, and an EBITDA loss of Rs 17.7 crore versus a loss of Rs 2.4 crore in the previous year.